Pharmacogenomic study feasibility assessment and pharmaceutical business decision-making

Methods in Pharmacology and Toxicology

Volumn , Issue , 2008, Pages 253-265

  Franc, Monique ^a   Frangiosa, Theresa ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b NONE

Author keywords

business decision making; clinical trials; commercial; multi attribute decision analysis (MADA); pharmaceutical industry; Pharmacogenomics; sensitivity analysis; study feasibility

Indexed keywords

CLINICAL EVALUATION; COMMERCIAL PHENOMENA; DECISION MAKING; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOSE RESPONSE; DRUG COST; DRUG DESIGN; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; FEASIBILITY STUDY; HUMAN; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW; SENSITIVITY ANALYSIS;

EID: 78649428239     PISSN: 15572153     EISSN: 19406053     Source Type: Book Series    
DOI: 10.1007/978-1-59745-439-1_13     Document Type: Review

References (5)

1. Bernard S (2003) The five myths of pharmacogenomics. Pharm Exec (October issue).
2. Mollaghasemi M, Pet-Edwards J (1997) Technical briefing: making multiple-objective decisions. IEEE Computer Society Press, Los Altimos, CA.
3. Yoon KP, Hwang C (1995) Multiple attribute decision making: an introduction. Sage Publications, Thousand Oaks, CA.
4. Prato T (1999) Multiple attribute decision analysis for ecosystem management. Ecol Econ 30(2):207-22.
5. Whitney R, Wilson J (1981) Multi-attribute decision analysis approach to the development of a computerized aid to mission planning (MADCAMP) [Master's Thesis].